Our Leading AI-Driven Drug
Discovery Pipeline
Our expansive therapeutic pipeline exemplifies the power of the Recursion OS. With every new discovery, our platform gets smarter, leading to pipeline growth.
We’re committed to building a pipeline in indications with potential for accelerated path to approval to reach patients faster, with a focus on Precision Oncology and Rare Diseases
~185,0001
REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.
Learn more on clinicaltrials.gov.
REC-1245 targets RBM39, a novel CDK12-adjacent target identified by the Recursion OS. We believe we can modulate this target to produce a therapeutic effect in biomarker-enriched solid tumors and lymphoma.
~41,0002
REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.
~45,0003
REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.
~360K4
REC-994 is an orally bioavailable small molecule superoxide scavenger being developed for the treatment of CCM. CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the US, France, Germany, Italy, Spain and the UK. In Phase 1 trials in healthy volunteers that Recursion conducted, REC-994 demonstrated tolerability and suitability for chronic dosing. Our Phase 2 SYCAMORE clinical trial met its primary endpoint of safety and demonstrated encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose, seeing reductions in lesion volume and hemosiderin ring size.
Learn more on clinicaltrials.gov.
~50K5
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. There are currently no FDA-approved therapies for the treatment of FAP, a rare tumor predisposition syndrome affecting approximately 50,000 people in the US, France, Germany, Italy, Spain and the UK.
Learn more on clinicaltrials.gov.
~33K6
REC-2282 is a CNS-penetrant, orally bioavailable, small molecule pan-HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas. There are currently no FDA-approved drugs for the treatment of patients with NF2, an inherited genetic syndrome that can cause a variety of benign tumors in the central nervous system, including meningiomas. This molecule appears to be well tolerated, including in patients dosed for multiple years, and potentially has reduced cardiac toxicity that would differentiate it from other HDAC inhibitors. Its oral bioavailability and CNS penetrance distinguish it from currently approved HDAC inhibitors.
Learn more on clinicaltrials.gov.
>7,8007
REV102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.
~175K8
REC-3964 represents a potential first-in-class, oral, non-antibiotic, novel small molecule approach designed to selectively inhibit the toxin produced by Clostridioides difficile in the gastrointestinal tract. This molecule has the potential, when used as part of a treatment regimen, to prevent recurrent disease and/or other forms of C. diff infection, which is a leading cause of antibiotic-induced diarrhea sometimes leading to significant morbidity and mortality. More than 29,000 patients die in the US every year from C. diff infection. REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events.
Learn more on clinicaltrials.gov.
~50K9
Target Epsilon represents a potential first-in-class novel chemical entity for the treatment of an undisclosed indication in Fibrosis with compelling early data. Compelling activity was demonstrated in a gold standard animal model of a fibrotic disease with significant unmet need.
Advanced Solid Tumors
~185,0001
REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.
Learn more on clinicaltrials.gov.
Biomarker-Enriched Solid Tumors and Lymphoma
REC-1245 targets RBM39, a novel CDK12-adjacent target identified by the Recursion OS. We believe we can modulate this target to produce a therapeutic effect in biomarker-enriched solid tumors and lymphoma.
B-Cell Malignancies
~41,0002
REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.
Small-Cell Lung Cancer
~45,0003
REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.
Cerebral Cavernous Malformation
~360K4
REC-994 is an orally bioavailable small molecule superoxide scavenger being developed for the treatment of CCM. CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the US, France, Germany, Italy, Spain and the UK. In Phase 1 trials in healthy volunteers that Recursion conducted, REC-994 demonstrated tolerability and suitability for chronic dosing. Our Phase 2 SYCAMORE clinical trial met its primary endpoint of safety and demonstrated encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose, seeing reductions in lesion volume and hemosiderin ring size.
Learn more on clinicaltrials.gov.
Familial Adenomatous Polyposis
~50K5
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. There are currently no FDA-approved therapies for the treatment of FAP, a rare tumor predisposition syndrome affecting approximately 50,000 people in the US, France, Germany, Italy, Spain and the UK.
Learn more on clinicaltrials.gov.
Neurofibromatosis Type 2
~33K6
REC-2282 is a CNS-penetrant, orally bioavailable, small molecule pan-HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas. There are currently no FDA-approved drugs for the treatment of patients with NF2, an inherited genetic syndrome that can cause a variety of benign tumors in the central nervous system, including meningiomas. This molecule appears to be well tolerated, including in patients dosed for multiple years, and potentially has reduced cardiac toxicity that would differentiate it from other HDAC inhibitors. Its oral bioavailability and CNS penetrance distinguish it from currently approved HDAC inhibitors.
Learn more on clinicaltrials.gov.
Hypophosphatasia
>7,8007
REV102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.
Clostridioides difficile Infection
~175K8
REC-3964 represents a potential first-in-class, oral, non-antibiotic, novel small molecule approach designed to selectively inhibit the toxin produced by Clostridioides difficile in the gastrointestinal tract. This molecule has the potential, when used as part of a treatment regimen, to prevent recurrent disease and/or other forms of C. diff infection, which is a leading cause of antibiotic-induced diarrhea sometimes leading to significant morbidity and mortality. More than 29,000 patients die in the US every year from C. diff infection. REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events.
Learn more on clinicaltrials.gov.
Idiopathic Pulmonary Fibrosis
~50K9
Target Epsilon represents a potential first-in-class novel chemical entity for the treatment of an undisclosed indication in Fibrosis with compelling early data. Compelling activity was demonstrated in a gold standard animal model of a fibrotic disease with significant unmet need.
~10 advanced discovery programs
More than a dozen additional early discovery and research programs in oncology or with our partners - first program already optioned by Roche-Genentech in GI-oncology.
At Recursion Pharmaceuticals, we are committed to radically improving the lives of patients and their families by developing therapies that will make a lasting, positive, and transformative impact on diseases and conditions for which there are high unmet needs.
We believe that the best way to succeed in our mission is through well-designed clinical trials that determine the safety and effectiveness of investigational medicines. We understand that in some rare and specific circumstances, when enrollment into a clinical trial is not possible, physicians caring for patients with serious or life-threatening conditions or diseases may seek special access to investigational medicines. When appropriate and through an expanded access protocol, Recursion will consider individual Expanded Access, sometimes called “Compassionate Use” or “Early Access”, requests for an investigational medicine outside of an ongoing clinical trial for the indication being investigated by the company.
There may be additional requirements, but to start, a licensed treating physician must submit the request for Expanded Access in writing by contacting ExpandedAccess@Recursion.com. The physician must be able and willing to obtain a treatment IND, or regional equivalent, and Institutional Review Board or Ethics Committee approval, for the patient prior to initiating treatment with our investigational medicine.
We will consider applications to provide the investigational drug that will not, among other things, compromise the scientific validity of our broader development programs, or interfere with or delay clinical trials or regulatory filings designed to make the drug available to a larger patient population.
We endeavor to respond to Expanded Access requests within one week after the steps for submission are completed.
It is important to remember that investigational medicinal products have not yet received regulatory approval; thus, their potential risks and benefits are not yet established. Physicians and patients should consider all possible benefits and risks when seeking access to an investigational medicinal product. For information on available clinical trials visit: www.ClinicalTrials.gov.
Recursion is committed to maintaining the highest level of integrity and ethics across all clinical trials and investigational programs, including the timely and transparent disclosure of clinical trial information and results.
All company-sponsored Phase 2 and 3 clinical trials are posted on country-specific registries of clinical trials, such as clinicaltrials.gov. As part of our commitment to advancing science in the therapeutic areas in which we work, Recursion discloses results of these trials on public registries within 12 months following the trial completion date. To keep our patients informed, clinical trial results will be made available to participants in that trial upon request. Additionally, Recursion aims to submit an abstract of the primary analysis of clinical trial results for publication regardless of trial outcome or regulatory approval status.
to spend less and go faster
By leveraging technology at every step of the process, we can accelerate the development of high potential drug candidates once we have validated their potential.
.jpg){kind=link}